Laboratorios Farmaceuticos ROVI
Research Laboratorios Farmaceuticos ROVI (ROVI) on Bullrun: market cap EUR 3.11B, P/E 16.8, dividend yield 1.6%. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerROVI
- ExchangeMC
- CountrySpain
- SectorHealthcare
- IndustryDrug Manufacturers - Specialty & Generic
- CurrencyEUR
- Market capEUR 3.11B
- P/E16.8
- Dividend yield1.6%
- Financial periodQ2 2026
- RevenueEUR 191.67M
- Net incomeEUR 75.00M
- Free cash flowEUR 58.57M
- Gross margin68.7%
Valuation Snapshot
latest market cap is EUR 3.11B; P/E is 16.8; dividend yield is 1.6%.
Peer valuation comparison
Latest P/E is 16.81x versus a Healthcare sector median of 24.46x (31.3% below).
Latest dividend yield is 1.58% versus a Healthcare sector median of 2.11% (25.1% below).
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | EUR 743.48M | EUR 140.44M | EUR 119.27M | 64.9% | n/a | EUR 97.98M | EUR 121.72M | EUR 664.42M |
| FY2024 | EUR 763.75M | EUR 136.88M | EUR 79.16M | n/a | 2.67 | EUR 27.19M | EUR 90.72M | EUR 572.03M |
| FY2023 | EUR 829.51M | EUR 170.30M | EUR 59.45M | n/a | 3.2 | EUR 25.32M | EUR 52.24M | EUR 539.39M |
| FY2022 | EUR 817.70M | EUR 199.67M | EUR 186.88M | n/a | 3.73 | EUR 124.95M | EUR 59.44M | EUR 521.38M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-29 | EUR 3.11B | 16.8 | 1.6% | 0.96 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0.96 EUR, yield 1.6%.
| Year | Dividends/share |
|---|---|
| FY2024 | 1.1 EUR |
| FY2023 | 1.29 EUR |
| FY2022 | 0.96 EUR |
About Laboratorios Farmaceuticos ROVI
Laboratorios Farmaceuticos Rovi, S.A. manufactures, sells, and markets pharmaceutical products in Spain, European Union, OECD countries, and internationally. The company offers prescription products, including Ameride, Bertanel, Bluxam, Enoxaparin Rovi, Calcium Vitamine D3 Rovi, Exxiv, Prinvil, Rhodogil, Glufan, Hibor, Hirobriz Breezhaler, Neparvis, Mysimba, Orvatez, Tryptizol, Ulunar Breezhaler, and Volutsa.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Laboratorios Farmaceuticos ROVI's market cap?
Laboratorios Farmaceuticos ROVI's market capitalization is EUR 3.11B.
What is Laboratorios Farmaceuticos ROVI's P/E ratio?
Laboratorios Farmaceuticos ROVI's price-to-earnings (P/E) ratio is 16.8.
Does Laboratorios Farmaceuticos ROVI pay a dividend?
Laboratorios Farmaceuticos ROVI has a dividend yield of 1.6%.
What does Laboratorios Farmaceuticos ROVI do?
Laboratorios Farmaceuticos Rovi, S.A. manufactures, sells, and markets pharmaceutical products in Spain, European Union, OECD countries, and internationally. The company offers prescription products, including Ameride, Bertanel, Bluxam, Enoxaparin Rovi, Calcium Vitamine D3 Rovi, Exxiv, Prinvil, Rhodogil, Glufan, Hibor, Hirobriz Breezhaler, Neparvis, Mysimba, Orvatez, Tryptizol, Ulunar Breezhaler, and Volutsa.